Cell cycle proteins that are often dysregulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracted considerable interest as potential targets for cancer therapy. In this context, multiple inhibitors of CDK4 and CDK6 have been developed, including three small molecules (palbociclib, abemaciclib and ribociclib) that are currently approved for the treatment of patients with breast cancer and are being extensively tested in individuals with other solid and haematological malignancies. Accumulating preclinical and clinical evidence indicates that the anticancer activity of CDK4/CDK6 inhibitors results not only from their ability to block the cell cycle in malignant cells but also from a range of immunostimulatory effects. In this Review, we discuss the ability of anticancer cell cycle inhibitors to modulate various immune functions in support of effective antitumour immunity.

中文翻译：

---

通过抗癌细胞周期抑制剂进行免疫调节。

在恶性细胞中经常失调的细胞周期蛋白，如细胞周期蛋白依赖性激酶 4 (CDK4) 和 CDK6，作为癌症治疗的潜在靶标引起了相当大的兴趣。在此背景下，已开发出多种 CDK4 和 CDK6 抑制剂，包括三种小分子（palbociclib、abemaciclib 和 ribociclib），目前已获批用于治疗乳腺癌患者，并正在对患有其他实体瘤和血液系统恶性肿瘤的个体进行广泛测试. 积累的临床前和临床证据表明，CDK4/CDK6 抑制剂的抗癌活​​性不仅源于它们阻断恶性细胞细胞周期的能力，还源于一系列免疫刺激作用。在这篇评论中，